Bivalirudin anticoagulation for a patient with hypercoagulable immune syndromes undergoing mitral valve surgery.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16731183.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Unfractionated heparin has been a near universal anticoagulant for cardiac surgery; however it is contraindicated in heparin-induced thrombocytopenia type II. Alternative anticoagulants such as bivalirudin (a direct thrombin inhibitor) are being utilized. Bivalirudin was successfully used in an immunologically complex patient (diagnoses of heparin-induced thrombocytopenia type II, systemic lupus erythematosus, antiphospholipid syndrome, and dialysis-dependent renal failure) requiring cardiopulmonary bypass. Thrombotic events are common in antiphospholipid syndrome patients undergoing cardiac surgery utilizing high-dose heparin. This may represent unrecognized heparin-induced thrombocytopenia type II. Our patient did not experience perioperative thrombotic or bleeding complications. The possible cross-reactivity between heparin induced thrombocytopenia type II and antiphospholipid syndrome has not been investigated.
Medical subject headings
- Anticoagulants
- Antiphospholipid Syndrome
- Autoantibodies
- Heparin
- Lupus Erythematosus, Systemic
- Mitral Valve Insufficiency
- Peptide Fragments
- Thrombocytopenia
- Thrombophilia